COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00066677
Recruitment Status : Completed
First Posted : August 7, 2003
Last Update Posted : June 19, 2013
Information provided by:
Fox Chase Cancer Center

Brief Summary:

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining bevacizumab with docetaxel may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying bevacizumab and docetaxel to see how well they work compared to bevacizumab alone in treating patients with metastatic pancreatic cancer.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Biological: bevacizumab Drug: docetaxel Phase 2

Detailed Description:


  • Determine the progression-free survival of patients with previously treated metastatic pancreatic adenocarcinoma treated with bevacizumab with or without docetaxel.
  • Determine the objective response rate and overall survival of patients treated with these regimens.
  • Determine the incidence of thromboembolic events in patients treated with these regimens.

OUTLINE: This is a randomized, open-label study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and docetaxel IV over 1 hour on days 1, 8, and 15.
  • Arm II: Patients receive bevacizumab as in arm I. In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 46 patients (23 per treatment arm) will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II and Coagulation Study of rhuMAb-VEGF With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
Study Start Date : October 2003
Actual Primary Completion Date : November 2008
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Progression-free survival

Secondary Outcome Measures :
  1. Objective response rate
  2. Overall survival
  3. Incidence of thromboembolic events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the pancreas

    • Metastatic disease
  • Unidimensionally measurable disease outside of the pancreas

    • At least 1 lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
  • Must have received 1, and only 1, prior gemcitabine-containing regimen for metastatic disease unless disease has recurred within 6 months after treatment with neoadjuvant or adjuvant gemcitabine-containing therapy
  • No brain metastases



  • 18 and over

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • WBC at least 3,000/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 9.0 g/dL (transfusion allowed)
  • No bleeding diathesis or coagulopathy


  • Bilirubin no greater than upper limit of normal (ULN)
  • AST and ALT no greater than 1.5 times ULN
  • INR no greater than ULN
  • PTT no greater than ULN


  • Creatinine no greater than 2.0 mg/dL
  • No clinically significant renal impairment
  • Urine protein:creatinine ratio ≥ 1.0


  • No prior myocardial infarction
  • No prior stroke
  • No clinically significant cardiovascular disease
  • No uncontrolled hypertension (i.e., blood pressure greater than 160/110 mm Hg on medication)
  • No unstable angina
  • No New York Heart Association class II-IV congestive heart failure
  • No serious cardiac dysrhythmia requiring medication
  • No peripheral vascular disease


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No history or evidence of CNS disease (e.g, primary brain tumor or seizures not controlled with standard medical therapy)
  • No other medical condition that would preclude study participation
  • No psychiatric condition that would preclude study participation
  • No other prior or concurrent malignancy that would preclude study participation
  • No significant traumatic injury within the past 28 days
  • No serious, nonhealing wound, ulcer, or bone fracture


Biologic therapy

  • No concurrent prophylactic granulocyte or platelet growth factors


  • See Disease Characteristics
  • More than 4 weeks since prior chemotherapy

Endocrine therapy

  • Not specified


  • At least 4 weeks since prior radiotherapy


  • More than 7 days since prior fine needle aspirations or core biopsies
  • More than 28 days since prior surgery (except closed biopsy or access port placement)
  • More than 28 days since prior open biopsy
  • No concurrent surgery


  • More than 4 weeks since prior experimental drug study participation
  • More than 4 weeks since prior investigational drugs
  • No other concurrent experimental drug study participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00066677

Layout table for location information
United States, Pennsylvania
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania, United States, 19111-2497
Sponsors and Collaborators
Fox Chase Cancer Center
Layout table for investigator information
Study Chair: Steven J. Cohen, MD Fox Chase Cancer Center
Layout table for additonal information Identifier: NCT00066677    
Other Study ID Numbers: CDR0000316454
P30CA006927 ( U.S. NIH Grant/Contract )
First Posted: August 7, 2003    Key Record Dates
Last Update Posted: June 19, 2013
Last Verified: May 2013
Keywords provided by Fox Chase Cancer Center:
adenocarcinoma of the pancreas
recurrent pancreatic cancer
stage IV pancreatic cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action